Adult Dosing
Acute migraine attacks (with or without aura)
- 25-100 mg PO x 1
- May repeat q2 hrs if headache recurs
- Max: 200 mg/24 hrs
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
- Sumatriptan should be given only if a clear diagnosis of migraine has been established
- If the patient does not respond to the first dose, reconsider diagnosis of migraine headache before administration of a second dose
- Sumatriptan is not indicated for prophylaxis of migraine or for use in the management of hemiplegic or basilar migraine
- Safety and effectiveness have not been established for cluster headache
- Sumatriptan should not be given when risk factors for ischemic, cerebrovascular, or peripheral vascular syndromes are present. Unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors e.g. hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age. Do not use unless a cardiovascular evaluation establishes that the patient does not have CAD
- Serious adverse cardiac events, including acute MI, arrhythmias, and death, have been reported within a few hours following administration
- It may cause coronary vasospasm in patients with history of coronary artery disease (CAD)
- Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have occurred with 5-HT1 agonists
- Intermittent long term users should undergo periodic cardiovascular evaluation
- Monitor BP at baseline, cardiovascular evaluation at baseline, then periodically during long-term treatment if risk factors present
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Diabetes Mellitus
- Concomitant use with SSRI's possible serotonin syndrome
- Hypertension (due to possibility of unrecognised CAD)
- Cardiac risk factors
- Hx of seizure disorder
- Geriatric population (due to presence of risk factors for hypertension, hypercholesterolemia, possibility of unrecognized CAD)
Pregnancy Category:C
Breastfeeding: Sumatriptan is excreted in breastmilk in low levels. It has poor oral bioavailability, thus would not be expected to cause any adverse effects in most breastfed infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 28 August2010). Manufacturer advises caution.
US Trade Name(s)
US Availability
sumatriptan (generic)
Imitrex
Canadian Trade Name(s)
Canadian Availability
sumatriptan (generic)
Imitrex DF
UK Trade Name(s)
- Imigran
- Imigran Radis
- Imigran Recovery
- Migraleve Ultra
UK Availability
sumatriptan (generic)
Imigran, Imigran Radis
Imigran Recovery, Migraleve ultra
Australian Trade Name(s)
- Imigran
- Imigran FDT
- Sumagran
- Sumatab
- Suvalan
Australian Availability
sumatriptan (generic)
Imigran
Imigran FDT
- FDT (fast disintegrating tablets): 50, 100 mg
Sumagran, Sumatab, Suvalan
Pricing data from www.DrugStore.com in U.S.A.
- SUMAtriptan Succinate 50 MG TABS [Box] (RANBAXY PHARMACEUTICALS)
9 mg = $199.99
27 mg = $569.97 - Imitrex 100 MG TABS [Box] (GLAXO SMITH KLINE)
9 mg = $255
27 mg = $754 - Imitrex 50 MG TABS [Box] (GLAXO SMITH KLINE)
9 mg = $268.99
27 mg = $780.99 - Imitrex 25 MG TABS [Box] (GLAXO SMITH KLINE)
9 mg = $272.65
27 mg = $791.5
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
